Apr 28, 2020
PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With Aplidin® (Plitidepsin) for the Treatment of Patients With COVID-19
Feb 17, 2020
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
Jan 30, 2020
Soft Tissue Sarcoma Market Size is Expected to Increase With a CAGR of 6.47% During Study Period for 7MM as per DelveInsight's Analysis
Jan 27, 2020
PharmaMar and Bionical Emas Launch Expanded Access Program for Lurbinectedin in Relapsed Small Cell Lung Cancer in the U.S.
Jan 22, 2020
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
Dec 19, 2019
PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S.
Oct 14, 2019
STA To Market Sarcoma Drug In Australia, New Zealand And SE Asia Following License Deal
Aug 19, 2019
PharmaMar will submit NDA for lurbinectedin under accelerated approval in SCLC in the USA
Dec 11, 2018
World-first Approval For Multiple Myeloma Drug APLIDIN(R)
Oct 19, 2018
Sylentis, PharmaMar Group, Announces the End of Patient Recruitment for its HELIX Trial
Sep 06, 2018
PharmaMar Will Present the Results of the Phase I/II Study With Lurbinectedin in Combination With Doxorubicin in Relapsed Small-cell Lung Cancer During the IASLC World Conference
Aug 03, 2018
The U.S. Food and Drug Administration (FDA) Has Granted Orphan Drug Designation to PharmaMar's Lurbinectedin
Jul 31, 2018
PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment
Jul 30, 2018
Impilo Launches Immedica - a Platform for Pan-European Niche Specialty Pharma Launch, Commercialization and Distribution Services
Jul 27, 2018
PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe
Jun 26, 2018
PharmaMar and Chugai Agree to Terms for Early Termination of the License Agreement for Zepsyre® in Japan
Jun 11, 2018
PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® With Pint Pharma International
Jun 05, 2018
PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin
Jun 04, 2018
PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018
May 29, 2018
Positive Recommendation of IDMC to Zepsyre® to Continue the Phase III Trial Within Small-cell Lung Cancer (ATLANTIS)